1,243,513 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Nantahala Capital Management LLC

Nantahala Capital Management LLC bought a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,243,513 shares of the company’s stock, valued at approximately $1,965,000. Nantahala Capital Management LLC owned approximately 3.56% of RAPT Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in RAPT. Picton Mahoney Asset Management raised its holdings in shares of RAPT Therapeutics by 994.4% in the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after buying an additional 14,697 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of RAPT Therapeutics by 9.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock worth $348,000 after buying an additional 18,558 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after buying an additional 25,130 shares during the period. Barclays PLC raised its holdings in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after buying an additional 29,195 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of RAPT Therapeutics by 4.9% in the fourth quarter. Geode Capital Management LLC now owns 716,937 shares of the company’s stock worth $1,133,000 after buying an additional 33,758 shares during the period. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of RAPT Therapeutics in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, RAPT Therapeutics currently has an average rating of “Hold” and a consensus price target of $4.00.

RAPT Therapeutics Trading Up 0.5 %

Shares of NASDAQ:RAPT opened at $0.88 on Monday. RAPT Therapeutics, Inc. has a twelve month low of $0.75 and a twelve month high of $8.58. The company’s 50 day moving average is $1.09 and its 200 day moving average is $1.31. The company has a market cap of $115.98 million, a PE ratio of -0.32 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). Equities research analysts predict that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.